Imreg, Inc.
🏢 View company profile →12Patents
0Active
12Granted
29Portfolio score
Filing activity: Jun 17, 1982 → Mar 29, 1990
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4699898A | Tripeptides affecting immune response | Human Necessities | 28 | Expired |
| US4751216A | Methods for treating AIDS and ARC | Emerging Cross-Sectional Technologies | 18 | Expired |
| US4778750A | Diagnostic methods for immune function | Emerging Cross-Sectional Technologies | 17 | Expired |
| US4490472A | Sensitive tests for malignancies based on DNA detection | Emerging Cross-Sectional Technologies | 13 | Expired |
| US4710380A | Treatment of autoimmune disorders with immunoamplifiers | Emerging Cross-Sectional Technologies | 13 | Expired |
| US4616079A | Immunoamplifiers and processes for the extraction thereof | Emerging Cross-Sectional Technologies | 7 | Expired |
| US5013546A | Methods for modulating antibody production in treating patients with AIDS, ARC and other diseases | Human Necessities | 4 | Expired |
| US5100663A | Tyr-Gly compositions useful in increasing immune response | Emerging Cross-Sectional Technologies | 4 | Expired |
| US5093321A | Dialysates for treating aids and arc and for otherwise increasing immune response | Human Necessities | 4 | Expired |
| US5081108A | Method of showing progression of AIDS in an ARC patient by treating with Tyr-Gly compositions | Human Necessities | 3 | Expired |
| US4920097A | Immunosuppressor and method of extraction thereof from leukocytes | Emerging Cross-Sectional Technologies | 2 | Expired |
| US4874608A | Therapeutic method for treating malignancies | Human Necessities | 1 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.